Stay updated on Carboplatin/Nab-Paclitaxel + Pembrolizumab in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Carboplatin/Nab-Paclitaxel + Pembrolizumab in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Carboplatin/Nab-Paclitaxel + Pembrolizumab in NSCLC Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    A new site-wide notice states that information may not be up to date due to a lapse in government funding and directs users to update status at opm.gov. The page revision has been updated from v3.4.0 to v3.4.1.
    Difference
    0.4%
    Check dated 2026-02-04T06:32:51.000Z thumbnail image
  2. Check
    8 days ago
    Change Detected
    Summary
    The changes are minor UI/text updates: a 'Show glossary' addition, capitalization adjustments for QC criteria labels, a 'No FEAR Act Data' label, and a new 'Revision: v3.4.0' label replacing the previous 'v3.3.4'. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2026-01-28T04:32:59.000Z thumbnail image
  3. Check
    15 days ago
    No Change Detected
  4. Check
    22 days ago
    Change Detected
    Summary
    Revision updated from v3.3.3 to v3.3.4; no visible changes to the study content or page layout were detected. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-01-14T02:22:12.000Z thumbnail image
  5. Check
    44 days ago
    Change Detected
    Summary
    A consolidated Locations section now lists California, Illinois, Indiana, and Virginia, replacing the former separate California Locations, Illinois Locations, Indiana Locations, and Virginia Locations subsections; the HHS Vulnerability Disclosure link was removed.
    Difference
    0.5%
    Check dated 2025-12-23T10:14:42.000Z thumbnail image
  6. Check
    66 days ago
    Change Detected
    Summary
    Minor site-wide update applied: Revision v3.3.2 replaces v3.3.1; no changes to the study details, eligibility criteria, or results. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2025-12-01T17:52:37.000Z thumbnail image
  7. Check
    73 days ago
    Change Detected
    Summary
    The page shows a new Revision: v3.3.1 and removal of Revision: v3.2.0, indicating a minor backend or metadata update without changing the trial details presented. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2025-11-24T14:45:40.000Z thumbnail image

Stay in the know with updates to Carboplatin/Nab-Paclitaxel + Pembrolizumab in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Carboplatin/Nab-Paclitaxel + Pembrolizumab in NSCLC Clinical Trial page.